Drug intelligence / Profile preview

cefamandole + tobramycin

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Cefamandole + tobramycin is a combination of two antibiotics used primarily for the treatment of severe infections caused by susceptible Gram-negative and some Gram-positive bacteria. Cefamandole is a second-generation cephalosporin (beta-lactam) antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. Tobramycin is an aminoglycoside antibiotic that binds to the bacterial 30S and 50S ribosomal subunits, preventing formation of the 70S initiation complex and thereby inhibiting protein synthesis, resulting in bactericidal activity. The combination has been shown to act synergistically against certain pathogens and is used in clinical settings for serious infections such as septicemia, lower respiratory tract infections, urinary tract infections, peritonitis, skin/soft tissue infections, and bone/joint infections. This regimen may be associated with nephrotoxicity but can be effective when other options are limited[1][4][5][8].

02

Targets

PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on cefamandole + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefamandole + tobramycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call